Pulse Biosciences, Inc.

Equities

PLSE

US74587B1017

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX 03:23:57 2024-07-11 pm EDT 5-day change 1st Jan Change
15.91 USD +7.07% Intraday chart for Pulse Biosciences, Inc. +32.57% +30.51%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Softer Late Afternoon MT
Sector Update: Health Care Stocks Mixed in Afternoon Trading MT
Top Midday Gainers MT
Pulse Biosciences Shares Jump After FDA Breakthrough Device Designation for Cardiac Surgery System MT
Pulse Biosciences Hit 2-Year High on FDA Status for Surgery System DJ
Pulse Biosciences Receives US FDA Breakthrough Device Designation for nsPFA Cardiac Surgery System MT
Pulse Biosciences Gets FDA's Breakthrough Status for Surgery System DJ
Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation CI
Pulse Biosciences, Inc.(NasdaqCM:PLSE) dropped from Russell Microcap Value Index CI
Pulse Biosciences, Inc.(NasdaqCM:PLSE) dropped from Russell 2000 Value Index CI
Pulse Biosciences, Inc.(NasdaqCM:PLSE) dropped from Russell 3000 Value Index CI
Pulse Biosciences, Inc.(NasdaqCM:PLSE) dropped from Russell 2500 Value Index CI
Pulse Biosciences, Inc.(NasdaqCM:PLSE) dropped from Russell Small Cap Comp Value Index CI
Pulse Biosciences, Inc.(NasdaqCM:PLSE) dropped from Russell 3000E Value Index CI
Pulse Biosciences's Preliminary Results of Rights Offering Sets Final Subscription Price at $10 per Unit MT
Shelley D. Spray Does Not Stand for Reelection from the Board of Pulse Biosciences, Inc CI
Pulse Biosciences Moves New Record Date for Rights Offering MT
Pulse Biosciences Appoints Burke Barrett as President, CEO MT
Pulse Biosciences, Inc Announces CEO Changes CI
Pulse Biosciences, Inc Announces Executive Changes CI
Pulse Biosciences, Inc. Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System CI
Transcript : Pulse Biosciences, Inc., Q1 2024 Earnings Call, May 07, 2024
Pulse Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Sector Update: Health Care Stocks Slide Late Afternoon MT
Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans MT
Chart Pulse Biosciences, Inc.
More charts
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.
More about the company
  1. Stock Market
  2. Equities
  3. PLSE Stock
  4. News Pulse Biosciences, Inc.
  5. Pulse Biosciences Moves New Record Date for Rights Offering